Skip to main content
UploadLanguage (EN)Support
BusinessMobileSocial MediaMarketingTechnologyArt & PhotosCareerDesignEducationPresentations & Public SpeakingGovernment & NonprofitHealthcareInternetLawLeadership & ManagementAutomotiveEngineeringSoftwareRecruiting & HRRetailSalesServicesScienceSmall Business & EntrepreneurshipFoodEnvironmentEconomy & FinanceData & AnalyticsInvestor RelationsSportsSpiritualNews & PoliticsTravelSelf ImprovementReal EstateEntertainment & HumorHealth & MedicineDevices & HardwareLifestyle
Uploaded bySaimaKhan862443
PPTX, PDF479 views

"Pharmacology of Antihyperlipidemic Drugs"

This presentation provides an in-depth exploration of antihyperlipidemic drugs, a critical class of pharmacological agents used to manage dyslipidemia and prevent cardiovascular complications. It covers the classification of lipid-lowering agents, including statins, fibrates, niacin, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and newer therapeutic options. Detailed insights into their mechanisms of action, pharmacokinetics, therapeutic indications, adverse effects, and drug interactions are presented in a structured and educational format. This resource is especially valuable for students of pharmacy, medicine, and allied health sciences, as well as healthcare professionals seeking a clear and comprehensive understanding of the pharmacological management of hyperlipidemia.

Health & Medicine◦
Related topics:
Lipid Metabolism Overview•Clinical Pharmacy•
Download to read offline
ANTIHYPERLIPIDEMICS By: Saima Assistant professor Magadh institute of pharmacy
Hyperlipidemia • Hyperlipidemia refers to abnormally high levels of lipids (fats), such as cholesterol and triglycerides, in the blood. • It is a significant risk factor for cardiovascular diseases, including atherosclerosis, coronary artery disease, and stroke. Types of Hyperlipidemia: • Primary Hyperlipidemia: Caused by genetic factors, such as familial hypercholesterolemia. • Secondary Hyperlipidemia: Due to underlying conditions or lifestyle factors, such as: • Obesity • Diabetes • Hypothyroidism • Excessive alcohol consumption • High-fat diet • Sedentary lifestyle
Lipid Types Involved: Low-Density Lipoprotein (LDL-C): • "Bad cholesterol" that contributes to plaque formation in arteries. High-Density Lipoprotein (HDL-C): • "Good cholesterol" that helps remove LDL cholesterol from the bloodstream. Triglycerides (TG): • A type of fat stored in the body; elevated levels are harmful. Total Cholesterol (TC): • Combined measure of LDL, HDL, and other lipid components. VLDL : • VLDL is a type of lipoprotein produced by the liver. It primarily carries triglycerides to tissues for energy storage or use. After delivering triglycerides, VLDL particles are converted into LDL (low-density lipoprotein).
CLASSIFICATION OF ANTIHYPERLIPIDEMICS
HMG-CoA reductase inhibitors ( Statins) • Statins are the most commonly prescribed drugs for lowering cholesterol and preventing cardiovascular diseases. Examples: High Potency: Atorvastatin, Rosuvastatin. Moderate Potency: Simvastatin, Pravastatin, Fluvastatin Therapeutic Uses: oHyperlipidemia (high LDL levels). oPrevention of cardiovascular events (e.g., heart attack, stroke). oTreatment of atherosclerosis and related disorders.
MECHANISM OF ACTION OF STATINS 1. Inhibition of Cholesterol Synthesis: • Statins competitively inhibit HMG-CoA reductase, the key enzyme in cholesterol biosynthesis. • This blocks the conversion of HMG-CoA to mevalonate, a precursor of cholesterol.
2. Upregulation of LDL Receptors: • Reduced hepatic cholesterol levels trigger upregulation of LDL receptors on hepatocytes. • Increased LDL receptor expression enhances the clearance of LDL from the bloodstream. 3. Reduction in Plasma LDL Levels: • Enhanced LDL uptake lowers circulating LDL cholesterol levels, reducing the risk of atherosclerosis. 4. Increased HDL levels
Adverse effects ( HMG ) • Hepatotoxicity , headache • Myopathy – muscle pain, weakness • Gastrointestinal disturbances – Anorexia, nausea, vomiting, diarrhoea. • Contraindicated in pregnancy. Uses : • Used in both primary and secondary hyperlipidemias.
Bile Acid Sequestrants (Resins) • They are basic ion exchange resins. • They are neither digested nor absorbed in the gut. • They bind bile acids in the intestine interrupting their enteroheptic cycling. They promote conversion of cholesterol to bile acids in the liver.’ • They stimulate the formation of hepatic LDL-receptors which take up more LDL-cholesterol from the circulation. • The net effect is reduction of LDL levels with little effect on HDL levels. Adverse effects: Unpalatibility, bloating, nausea, constipation.
FIBRATES(Clofibrate, gemfibrozil, fenofibrate) • They activate peroxisome proliferator-activated receptor α (PPAR- α) present in the liver adipose tissue and skeletal muscle. Gemfibrozil – First line drug for patients with markedly raised TG levels. Most effective in type III hyperlipoproteinaemia. Epigastric distress, loose motion are common side effects. Use of combination of gemfibrozil with statins increases the risk of myopathy. (Fenofibrate, benzafibrate can be combined with statins)
NICOTINIC ACID • Niacin is a B-complex vitamin. In large doses, it has hypolipidaemic effect. • It reduces plasma TG, VLDL, LDL, and increases HDL levels. • It is highly efficacious in hypertriglyceridaemia ( type III, IV, V). • It is mostly used to lower VLDL and raise HDL levels. Adverse effect – Flushing, dyspepsia, hyperglycemia. Contraindicated in pregnancy.
Sterol absorbtion inhibitor ( Ezetimibe ) • It inhibits the absorption of dietary and biliary cholesterol in the intestine. • It is mainly used with a statin. • The combination of ezetimibe and statins has a beneficial effect. Statins inhibit cholesterol synthesis but increases intestinal cholesterol absorption. Ezetimibe inhibits intestinal cholesterol absorption but increses cholesterol synthesis. • Combination use of these drugs prevents the increase in cholesterol absorption caused by statins and increased cholesterol synthesis by ezetimibe.
"Pharmacology of Antihyperlipidemic Drugs"